ESMO Congress | Conference

Dr. Gonzalez-Martin on the Results of the PRIMA Trial in Ovarian Cancer

September 29th 2019

Antonio Gonzalez-Martin, MD, co-director, Department of Medical Oncology, Clinica Universidad de Navarra, discusses the results of the phase III PRIMA trial in advanced ovarian cancer.

Selpercatinib Shows Strong ORR in Thyroid Cancer, FDA Submission Expected

September 29th 2019

The highly selective RET inhibitor selpercatinib (formally LOXO-292) demonstrated robust objective response rates for patients with RET-mutant medullary thyroid cancer and in those with other RET fusion-positive thyroid cancer.

PD-L1 Assays Demonstrate

September 29th 2019

An exploratory biomarker substudy of Impassion130 demonstrated clinical activity of atezolizumab (Tecentriq) and nab-paclitaxel (Abraxane) in a subgroup of patients with triple-negative breast cancer who had immune cell PD-L1 expression by the SP142 immunohistochemistry assay, regardless of the site of the tumor sample.

Abemaciclib/Fulvestrant Improves Survival in HR+ Advanced Breast Cancer

September 29th 2019

The addition of the CDK4/6 inhibitor abemaciclib (Verzenio) to fulvestrant (Faslodex) led to a median 9.4-month overall survival benefit compared with fulvestrant with placebo in patients with hormone receptor–positive, HER2-negative advanced breast cancer who progressed on prior endocrine therapy.

Atezolizumab Combo Confirmed as Frontline Standard in Advanced Small Cell Lung Cancer

September 29th 2019

With follow-up of nearly 2 years, the addition of atezolizumab to first-line carboplatin plus etoposide for the treatment of extensive stage small cell lung cancer continues to demonstrate improved overall survival compared with placebo plus CP/ET.

Abemaciclib Activity Extends to HR+/HER2+ Breast Cancer

September 29th 2019

Adding abemaciclib (Verzenio) and endocrine therapy to trastuzumab (Herceptin) improved progression-free survival in advanced hormone receptor-positive, HER2-positive breast cancer versus trastuzumab and chemotherapy.

Ribociclib/Fulvestrant Combo Improves OS in Advanced HR+ Breast Cancer

September 29th 2019

The combination of ribociclib and fulvestrant led to an approximate 28% reduction in the risk of death compared with placebo and fulvestrant in postmenopausal patients with hormone receptor–positive, HER2-negative advanced breast cancer.

Neoadjuvant Pembrolizumab Combo Prolongs pCR in Phase III TNBC Study

September 29th 2019

Neoadjuvant treatment with the combination of pembrolizumab and chemotherapy extended pathological complete response rates by 13.6 percentage points compared with chemotherapy alone for patients with early triple-negative breast cancer.

Trilaciclib Delivers "Unexpected" Survival Boost in TNBC

September 29th 2019

The investigational CDK4/6 inhibitor trilaciclib unexpectedly improved survival in metastatic triple-negative breast cancer despite failing to meet a safety-related primary endpoint.

Experts Highlight Anticipated Research to Be Revealed at ESMO 2019

September 29th 2019

OncLive interviewed experts at the State of the Science Summits™ in September 2019 on anticipated research to be presented at the 2019 ESMO Congress.

Adding Atezolizumab May Improve Outcomes in HER2+ Breast Cancer With PD-L1 Expression

September 28th 2019

A numerical improvement in overall survival was realized with the addition of atezolizumab (Tecentriq) to ado-trastuzumab emtansine (T-DM1; Kadcyla) compared with T-DM1 alone.

Dr. Ramalingam on the OS Results of the FLAURA Trial in EGFR-Mutant NSCLC

September 28th 2019

Suresh S. Ramalingam, MD, discusses the overall survival (OS) results of the phase III FLAURA trial in patients with EGFR-mutant non–small cell lung cancer (NSCLC).

Dr. Weber on the Updated Analysis of the CheckMate-238 Trial in Melanoma

September 28th 2019

Jeffrey S. Weber, MD, PhD, discusses the updated analysis of the phase III CheckMate-238 trial in patients with resected stage III/IV melanoma.

Enfortumab Vedotin Plus Pembrolizumab Shows Promise in Urothelial Cancer

September 28th 2019

More than 70% of patients with cisplatin-ineligible locally advanced urothelial cancer had objective responses to the investigational antibody-drug conjugate enfortumab vedotin plus pembrolizumab (Keytruda).

Sacituzumab Govitecan Active in Heavily Pretreated Metastatic Urothelial Cancer

September 28th 2019

Sacituzumab govitecan demonstrated clinical activity with an overall response rate of 29% in patients with heavily pretreated metastatic urothelial carcinoma.

Frontline Olaparib/Bevacizumab Maintenance Combo Extends PFS in Ovarian Cancer

September 28th 2019

Frontline maintenance therapy with the combination of olaparib and bevacizumab improved median progression-free survival versus bevacizumab and placebo for patients with newly diagnosed, advanced ovarian cancer.

Frontline Nivolumab/Ipilimumab Combo Improves OS in Advanced NSCLC

September 28th 2019

The first-line combination of nivolumab and ipilimumab led to a clinically meaningful improvement in overall survival versus chemotherapy in patients with advanced non–small cell lung cancer, regardless of PD-L1 expression.

Niraparib Improves PFS as Frontline Maintenance in Ovarian Cancer

September 28th 2019

Frontline maintenance therapy with the PARP inhibitor niraparib improved median progression-free survival by 5.6 months compared with placebo for patients with newly diagnosed, advanced ovarian cancer who responded to platinum-based chemotherapy.

Osimertinib OS Data Herald New Frontline Standard for EGFR-Mutant NSCLC

September 28th 2019

Frontline treatment with osimertinib improved median overall survival by 6.8 months compared with erlotinib or gefitinib for patients with metastatic, EGFR-mutant non–small cell lung cancer.

Frontline Veliparib Shows Intriguing PFS Findings in VELIA Trial

September 28th 2019

The frontline combination of veliparib, carboplatin, and paclitaxel followed by maintenance veliparib monotherapy led to a 32% reduction in the risk of progression or death compared with placebo plus chemotherapy with placebo maintenance for patients with high-grade serous ovarian cancer.